Spyglass Capital Management LLC Decreases Holdings in Illumina, Inc. $ILMN

Key Points

• Spyglass Capital decreased its Illumina stake by 39.6% in Q3, selling 276,415 shares and ending the period with 422,150 shares worth about $40.09 million (0.28% of Illumina), making ILMN its 23rd largest holding.
• Analyst consensus remains a "Hold" with an average price target of $129.69 (6 Buys, 10 Holds, 2 Sells); recent divergent moves include JPMorgan cutting its target to $120 (neutral) while Guggenheim raised its target to $170 (buy).
• Illumina beat quarterly estimates, reporting $1.35 EPS vs. $1.26 expected and $1.16B in revenue vs. $1.10B, and set FY2026 guidance of $5.05–$5.20 EPS versus analyst forecasts around $4.51.

Spyglass Capital Management LLC decreased its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 39.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 422,150 shares of the life sciences company's stock after selling 276,415 shares during the period. Illumina accounts for approximately 2.1% of Spyglass Capital Management LLC's holdings, making the stock its 23rd biggest holding. Spyglass Capital Management LLC owned 0.28% of Illumina worth $40,092,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Quent Capital LLC bought a new stake in shares of Illumina in the 3rd quarter valued at approximately $29,000. Aster Capital Management DIFC Ltd bought a new position in shares of Illumina during the 3rd quarter valued at approximately $33,000. Mather Group LLC. purchased a new stake in Illumina during the 3rd quarter valued at $46,000. Evelyn Partners Investment Management LLP raised its holdings in Illumina by 4,927.3% during the 2nd quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company's stock valued at $49,000 after buying an additional 542 shares during the period. Finally, SJS Investment Consulting Inc. lifted its position in Illumina by 13,225.0% in the third quarter. SJS Investment Consulting Inc. now owns 533 shares of the life sciences company's stock worth $51,000 after buying an additional 529 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on ILMN shares. TD Cowen reaffirmed a "hold" rating on shares of Illumina in a research note on Wednesday, January 7th. JPMorgan Chase & Co. lowered their target price on shares of Illumina from $130.00 to $120.00 and set a "neutral" rating for the company in a report on Friday, February 6th. Guggenheim lifted their price target on shares of Illumina from $144.00 to $170.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Zacks Research downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Wednesday, December 31st. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Illumina in a research report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $129.69.

Insiders Place Their Bets

In related news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the sale, the senior vice president owned 16,321 shares in the company, valued at $1,896,173.78. This trade represents a 12.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.60% of the stock is owned by insiders.

Illumina Stock Performance

Shares of Illumina stock opened at $118.94 on Friday. The stock's fifty day moving average is $133.15 and its two-hundred day moving average is $119.81. The company has a market capitalization of $18.19 billion, a PE ratio of 21.82, a price-to-earnings-growth ratio of 2.21 and a beta of 1.45. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $155.53.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping analysts' consensus estimates of $1.26 by $0.09. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business's revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.